NAD Supplementation Shows Promise for Rare Premature Aging Diseases Driven by DNA Damage
A new review links NAD depletion via PARP hyperactivation to premature aging diseases, suggesting NAD supplements may slow progression.
Résumé
This review by Vilhelm Bohr (University of Copenhagen) synthesizes evidence that rare premature aging disorders — including Cockayne syndrome, Werner syndrome, Ataxia-telangiectasia, and Xeroderma Pigmentosum — share a common biochemical vulnerability: defective DNA repair triggers excessive PARP1 activation, which rapidly depletes cellular NAD+. This cascade impairs mitochondrial function and accelerates aging hallmarks. Preclinical models and emerging clinical data suggest that restoring NAD+ levels through supplementation (primarily nicotinamide riboside or NMN) can improve DNA repair capacity, reduce mitochondrial dysfunction, and alleviate disease features. The review argues these rare diseases serve as powerful models for understanding broader aging biology and identifying which individuals are most likely to benefit from NAD-based interventions.
Résumé détaillé
**Why This Matters:** NAD+ is a critical coenzyme involved in energy metabolism, DNA repair signaling, and mitochondrial function. Its levels decline with age across multiple species, and this decline has been linked to hallmarks of aging including genomic instability and mitochondrial dysfunction. Identifying populations where NAD depletion is most severe — and most causally relevant — could sharpen the clinical use of NAD supplements, which have produced inconsistent results in general aging trials.
**What Was Studied:** This review by Vilhelm Bohr examines a group of rare monogenic premature aging diseases — Werner syndrome, Cockayne syndrome, Bloom syndrome, Rothmund-Thomson syndrome, Ataxia-telangiectasia, and Xeroderma Pigmentosum — all caused by mutations in genes central to DNA repair and genome maintenance. The review synthesizes preclinical and emerging clinical evidence on whether NAD supplementation can mitigate disease features in these conditions.
**Key Mechanistic Pathway:** The unifying mechanism across these diseases is a feed-forward loop: defective DNA repair leads to persistent DNA damage, which hyperactivates PARP1 (poly-ADP-ribose polymerase 1). PARP1 consumes NAD+ at a high rate to generate poly-ADP-ribose (PAR) chains as a damage signal. This hyperparylation depletes cellular NAD+, impairing glycolysis and starving mitochondria of energy substrates. The review notes that mtPARP1 has a far lower Km for NAD (22 µM) than nuclear PARP1 (210 µM), meaning mitochondria are especially sensitive to NAD depletion. Compartmentalized NAD pools in mitochondria, nuclei, and cytosol each have distinct replenishment mechanisms, adding complexity to supplementation strategies.
**Key Results:** In Cockayne syndrome cells, reduced NAD+ abundance is a documented molecular hallmark. In mouse and other animal models of CS, Werner syndrome, and A-T, NAD supplementation improved mitochondrial function and DNA repair metrics. Clinical trials using nicotinamide riboside (NR, ~1 g/day, safe up to 3 g/day) or NMN have shown benefits in neurodegenerative contexts (Alzheimer's mouse models, Parkinson's disease patients) with a strong safety profile. The review highlights that clinical areas such as neurodegeneration, vision, and hearing appear most responsive, while musculoskeletal conditions show less benefit.
**Implications and Caveats:** The author argues that rare premature aging diseases — where the cause of NAD depletion is genetically defined and severe — represent ideal populations for NAD supplementation trials. Success in these diseases would validate the broader NAD-aging hypothesis and inform stratification of general aging populations. However, NAD decline in human tissues is not uniform across organ systems, and many clinical trials in healthy older adults have shown no measurable benefit, underscoring that disease-context and baseline NAD status likely determine treatment response.
Principales conclusions
- Defective DNA repair in premature aging diseases triggers PARP1 hyperactivation, rapidly depleting cellular NAD+ and causing mitochondrial dysfunction.
- Cockayne syndrome patient-derived cells show documented reductions in NAD+ as a key molecular feature.
- NAD supplementation (NR or NMN) improved DNA repair and mitochondrial function in preclinical models of CS, Werner syndrome, and A-T.
- Clinical benefits of NAD supplementation appear strongest in neurodegeneration, vision, and hearing; musculoskeletal conditions respond less.
- NR doses up to 3 g/day appear safe in humans, with minimal reported side effects across multiple trials.
Méthodologie
This is a narrative review article synthesizing preclinical (rodent, nematode, Drosophila, cell culture) and clinical evidence on NAD supplementation across rare premature aging diseases and general aging contexts. The author draws on published clinical trial data, molecular mechanistic studies, and disease model systems to construct a unified framework. No original experimental data were generated.
Limites de l'étude
This is a review article, not an original clinical trial, so causal conclusions about NAD supplementation efficacy in humans with these rare diseases remain preliminary. NAD decline in human tissues is non-uniform and not fully characterized, complicating dose and tissue-targeting decisions. Most supporting evidence comes from animal models, and the small patient populations in these rare diseases make powered clinical trials challenging.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :